company background image
RGEN

RepligenNasdaqGS:RGEN Stock Report

Market Cap

US$16.9b

7D

0.4%

1Y

108.7%

Updated

27 Sep, 2021

Data

Company Financials +
RGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

RGEN Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

Repligen Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Repligen
Historical stock prices
Current Share PriceUS$307.37
52 Week HighUS$144.36
52 Week LowUS$327.32
Beta0.90
1 Month Change11.44%
3 Month Change50.65%
1 Year Change108.70%
3 Year Change453.52%
5 Year Change914.42%
Change since IPO2,973.70%

Recent News & Updates

Shareholder Returns

RGENUS Life SciencesUS Market
7D0.4%0.8%0.1%
1Y108.7%56.4%35.3%

Return vs Industry: RGEN exceeded the US Life Sciences industry which returned 56.4% over the past year.

Return vs Market: RGEN exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is RGEN's price volatile compared to industry and market?
RGEN volatility
RGEN Beta0.90
Industry Beta0.97
Market Beta1

Stable Share Price: RGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: RGEN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19811,128Tony Hunthttps://www.repligen.com

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

Repligen Fundamentals Summary

How do Repligen's earnings and revenue compare to its market cap?
RGEN fundamental statistics
Market CapUS$16.90b
Earnings (TTM)US$99.93m
Revenue (TTM)US$508.51m

169.1x

P/E Ratio

33.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGEN income statement (TTM)
RevenueUS$508.51m
Cost of RevenueUS$207.19m
Gross ProfitUS$301.31m
ExpensesUS$201.38m
EarningsUS$99.93m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.82
Gross Margin59.25%
Net Profit Margin19.65%
Debt/Equity Ratio15.6%

How did RGEN perform over the long term?

See historical performance and comparison

Valuation

Is Repligen undervalued compared to its fair value and its price relative to the market?

169.1x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: RGEN ($323.26) is trading above our estimate of fair value ($144.9)

Significantly Below Fair Value: RGEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RGEN is poor value based on its PE Ratio (177.8x) compared to the US Life Sciences industry average (53.1x).

PE vs Market: RGEN is poor value based on its PE Ratio (177.8x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: RGEN is poor value based on its PEG Ratio (8.8x)


Price to Book Ratio

PB vs Industry: RGEN is overvalued based on its PB Ratio (11.1x) compared to the US Life Sciences industry average (6.1x).


Future Growth

How is Repligen forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

20.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGEN's forecast earnings growth (20.3% per year) is above the savings rate (2%).

Earnings vs Market: RGEN's earnings (20.3% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RGEN's revenue (17.1% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: RGEN's revenue (17.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RGEN's Return on Equity is forecast to be low in 3 years time (9.2%).


Past Performance

How has Repligen performed over the past 5 years?

38.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RGEN has high quality earnings.

Growing Profit Margin: RGEN's current net profit margins (19.7%) are higher than last year (10.2%).


Past Earnings Growth Analysis

Earnings Trend: RGEN's earnings have grown significantly by 38.5% per year over the past 5 years.

Accelerating Growth: RGEN's earnings growth over the past year (223%) exceeds its 5-year average (38.5% per year).

Earnings vs Industry: RGEN earnings growth over the past year (223%) exceeded the Life Sciences industry 56.9%.


Return on Equity

High ROE: RGEN's Return on Equity (6.2%) is considered low.


Financial Health

How is Repligen's financial position?


Financial Position Analysis

Short Term Liabilities: RGEN's short term assets ($983.8M) exceed its short term liabilities ($332.3M).

Long Term Liabilities: RGEN's short term assets ($983.8M) exceed its long term liabilities ($80.6M).


Debt to Equity History and Analysis

Debt Level: RGEN's debt to equity ratio (15.6%) is considered satisfactory.

Reducing Debt: RGEN's debt to equity ratio has reduced from 57% to 15.6% over the past 5 years.

Debt Coverage: RGEN's debt is well covered by operating cash flow (33.4%).

Interest Coverage: RGEN's interest payments on its debt are well covered by EBIT (10.9x coverage).


Balance Sheet


Dividend

What is Repligen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Tony Hunt (57 yo)

6.33yrs

Tenure

US$5,066,061

Compensation

Mr. Anthony J. Hunt, also known as Tony, has been the Chief Executive Officer and President of Repligen Corporation since May 21, 2015. Mr. Hunt served as Secretary of Repligen Corporation. He served as Ch...


CEO Compensation Analysis

Compensation vs Market: Tony's total compensation ($USD5.07M) is below average for companies of similar size in the US market ($USD11.36M).

Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RGEN's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: RGEN's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RGEN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.


Top Shareholders

Company Information

Repligen Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Repligen Corporation
  • Ticker: RGEN
  • Exchange: NasdaqGS
  • Founded: 1981
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$16.898b
  • Shares outstanding: 54.98m
  • Website: https://www.repligen.com

Number of Employees


Location

  • Repligen Corporation
  • Building 1
  • Suite 100
  • Waltham
  • Massachusetts
  • 2453
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 22:54
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.